Many patients are on a combination of an SGLT2 inhibitor with a GLP-1 receptor agonist or tirzepatide (a dual agonist) and have incredible success without adverse reactions, but we are still figuring out the patient characteristics that would put them at higher risk of poor outcomes. Bagley is the senior editor of Endocrine News
18 November 2022
Their lightweight design, high battery energy density, and customizable shapes make them ideal for drones, RC models, electric vehicles, portable devices, and even energy storage solutions
pg 183-193
Mistakes I see repeatedly: On the topical side: applying to damp skin, layering acids immediately, using too little product (a barely-visible film isn't enough), and leaving reconstituted products at room temperature for weeks
When BPC-157 is used in ex-vivo or cell culture systems, investigators still follow biosafety guidance related to handling human or animal tissues, disposing of biological waste, and documenting any unexpected findings